Light therapy for dry age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests a light-based therapy called photobiomodulation for dry age-related macular degeneration (AMD). It aims to see if this treatment can help preserve vision in the dry AMD eye, and includes people who have dry AMD in one eye and wet AMD in the other.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have dry AMD in one eye and wet AMD in the other eye.
- No large blind spot (geographic atrophy) in the center of the macula.
- No history of epilepsy.
- No other retinal diseases besides AMD.
- No cataracts worse than grade 2.
- You must not be on light-sensitive or certain eye-deposit medications (like tetracyclines, hydroxychloroquine, or amiodarone).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
This study tests an eye drop solution designed to treat wet age-related macular degeneration (AMD), a condition that causes blurry vision due to abnormal blood vessel growth. The treatment aims to reduce fluid and improve vision without the need for frequent eye injections.
This study is testing whether shining a special light on the eye, called photobiomodulation, can help people with dry age-related macular degeneration (AMD). If you have dry AMD and are willing to participate, you will receive the light treatment and be monitored.
This study tests whether low-level red-light therapy can help people with dry age-related macular degeneration (AMD), a common cause of vision loss in older adults. The therapy is a painless light treatment that you might receive in multiple sessions, and the study aims to see if it can slow or improve vision decline.
This study tests whether a special low-level laser treatment (photobiomodulation) can help people with an early form of age-related macular degeneration called reticular pseudodrusen. It may slow vision loss or protect your eyes from getting worse.
This trial tests a new light-based treatment for intermediate age-related macular degeneration (AMD), a common eye condition that can lead to vision loss. The goal is to see if it is safe and helps slow down the disease.
Hear when a new Photobiomodulation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.